Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials

Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials

The DNA vaccine, AV-1959D, targeting N-terminal epitope of Aβ peptide, has been proven immunogenic in mice, rabbits, and non-human primates, while its therapeutic efficacy has been shown in mouse models of Alzheimer's disease (AD). Here we report for the first time on IND-enabling biodistributi...

Full description

Bibliographic Details
Main Authors: Irina Petrushina, Armine Hovakimyan, Indira S. Harahap-Carrillo, Hayk Davtyan, Tatevik Antonyan, Gor Chailyan, Konstantin Kazarian, Maxim Antonenko, Amandine Jullienne, Mary M. Hamer, Andre Obenaus, Olga King, Karen Zagorski, Mathew Blurton-Jones, David H. Cribbs, Harry Lander, Anahit Ghochikyan, Michael G. Agadjanyan
Format: Article
Language:English
Published: Elsevier 2020-06-01
Series:Neurobiology of Disease
Subjects:
Alzheimer's disease (AD)
DNA Aβ-vaccine
Biodistribution
Safety toxicology
Magnetic resonance imaging (MRI)
Immunohistochemistry (IHC)
Online Access:http://www.sciencedirect.com/science/article/pii/S096999612030098X

Internet

http://www.sciencedirect.com/science/article/pii/S096999612030098X

Similar Items